Elizabeth Juneman, MD
Basic profileElizabeth Juneman is a Cardiology physician affiliated with University of Arizona. OpenAlex indexes 91 publications with 774 citations (h-index 15); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingClinical trials
- POsition of Leads in Advanced heaRt Failure: the POLAR Study
Sponsor: Sergio Thal, M.D.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20252 payments$78
- Bristol Myers SquibbProgram year20241 paymentResearch$15,531
- Bristol Myers SquibbProgram year20231 paymentResearch$36,711
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
56.9%Statin13.1%Rosuvastatin Calcium57%Atorvastatin Calcium43%Part D≥26 patientsBeta blocker9%Carvedilol48%Metoprolol Succinate38%Metoprolol Tartrate14%Part D<11 patients+ 8 more classes in this area
Cancer & immunology
16.1%Calcineurin inhibitor12%Tacrolimus81%Cyclosporine Modified19%Part D<11 patientsKinase inhibitor4.1%Sirolimus100%Part D≥13 patientsMetabolism & gastrointestinal
12.9%SGLT2 inhibitor6%Farxiga73%Jardiance27%Part D<11 patientsCorticosteroid2.9%Prednisone100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Eugene Bleecker, MD
University of Arizona
Jordan Karp, MD
University of Arizona
Eugene Chang, MD
University of Arizona
Ricklie Julian, MD
University of Arizona
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Martin Leon, MD
Columbia University Irving Medical Center
Gregg Fonarow, MD
Ronald Reagan UCLA Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”